Affitech's AT001 Enters Clinic, as Delisting Looms

Clinical testing of Affitech A/S' lead antibody, AT001/r84, began this week, just as the company enters its final weeks as a publicly quoted entity and prepares to become a private entity, wholly owned by Russian investors.

Next week, the antibody developer will learn the outcome of a tender process for the remaining 15 percent of its stock that is not already owned by its majority shareholder, Trans Nova Investments Ltd., or an allied entity, Krosalter Enterprises Ltd.